Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Dana-Farber Cancer Institute
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03316573CT.gov Pembrolizumab in Neoplasms or Lymphomas | — | Suspended | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Histiocytic Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Dana-Farber Cancer Institute | P2 | CCC · 53 |
| PI3K/MTOR INHIBITOR LY3023414 | National Cancer Institute (NCI) | P2 | CCC |
| Ivosidenib | National Cancer Institute (NCI) | P2 | CCC |
| Ulixertinib | National Cancer Institute (NCI) | P2 | CCC |
| Selpercatinib | National Cancer Institute (NCI) | P2 | CCC |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | CCC |
| Palbociclib | National Cancer Institute (NCI) | P2 | CCC |
| Olaparib | National Cancer Institute (NCI) | P2 | CCC |
| Larotrectinib | National Cancer Institute (NCI) | P2 | CCC |
+6 more in the Histiocytic Sarcoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- PI3K/MTOR INHIBITOR LY3023414National Cancer Institute (NCI)CCC
- IvosidenibNational Cancer Institute (NCI)CCC
- UlixertinibNational Cancer Institute (NCI)CCC
- SelpercatinibNational Cancer Institute (NCI)CCC
- 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)CCC
Citation
Floatz Terminal. Pembrolizumab in Histiocytic Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-histiocytic-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →